132 The Korean Journal of Internal Medicine : Vol. 22, No. 2, June 2007 damage to the endothelial cells. They also emphasized the importance of IL-2, TNF-a, and leukotrien metabolites, according to the literature5). Considering the fact that not only our own patients, but also the ones in various reports suffered from upper respiratory infection, there's no denying that an inflammatory response is a major triggering factor for this disease. Several trials have been done with using theophylline, diuretics, terbutaline, steroids, calcium antagonist, Ginkgo biloba extracts and plasmapheresis as medication for SCLS, yet none of them have proven to be effective6). Considering that this disease is self-limiting, conservative treatment in the acute phase is believed to be very important. This syndrome can be a fatal disease because cardiovascular collapse can occur in the initial capillary leak phase. Approximately one third of the cases died in the initial capillary leak phase. Therefore, fluid therapy is very important in SCLS since it reduces the mortality. Because shifting of fluid and protein by capillary hyperpermeability is the pathophysiology of this syndrome, massive crystalloid fluid therapy would not be effective during the acute attack and it exacerbates the pulmonary edema. According to Fishel et al, in case of capillary leak caused by infection or inflammation, using excessive crystalloid solution is not a good option because it could impede the oxygen supply to tissue by creating pulmonary edema, and too much normal saline could cause metabolic acidosis; therefore, using colloid solution such as albumin could be more efficient in this type of case7). When used with an equal amount with normal saline solution, albumin could reduce the inflammatory responses and help create an efficient oxygen supply in tissue. But albumin could be less effective if it's leaked, so pentastarch is more recommendable7). Though we don't exactly know how a big molecule gets out of the capillary at the acute phase of SCLS, injecting a higher molecular weight material than albumin could be effective, considering that hypoalbuminemia is present in SCLS. According to Atkinson et al, materials with a molecular weight less than 200,000 daltons can get out of the capillary8). Considering the fact that the mean molecular weight of Pentastarch is 264,000 daltons, injecting pentastarch as the initial fluid in the initial capillary leak stage could be efficient to prevent the cardiovascular collapse and pulmonary edema that's due to massive fluid therapy. We actually did see reduced edema and elevated blood pressure in our patients when they were supplied with 10% Pentastarch. Pentastarch has side effects such as PT prolongation. Therefore, Pentastarch could be very effective for the patients in their acute phase, but only if it's used cautiously enough to avoid a prolonged PT. SCLS is a very rare syndrome with only 60 cases having been worldwide, and only 1 case has been reported in Korea9). However the incidence rates are climbing and we have experienced 2 cases in the short term. We think this indicates that SCLS could be misdiagnosed as other disease such as idiopathic edema or polycythemia vera, and so it is treated in a wrong way that could lead to death from repetitive attacks. In conclusion, having an awareness of SCLS and effective treatment are very important. Physicians must be aware of this illness and be well prepared to treat this effectively when finding one of these patients, and the opportunity for conservative management must not be missed. Using 10% pentastarch during the acute phase of SCLS may be a key to a good prognosis and this treatment will eventually make the patients' lives better. REFERENCES 1) Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical oedema and shock due to increased capillary permeability. Am J Med 29:193- 216, 1960 2) Doubek M, Brychtova Y, Tomiska M, Mayer J. Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. Acta Haematol 113:150-151, 2005 3) Tahirkheli NK, Greipp PR. Treatment of the systemic capillary leak syndrome with terbutaline and theophylline: a case series. Ann Intern Med 130:905-909, 1999 4) Amoura Z, Papo T, Ninet J, Hatron PY, Guillaumie J, Piette AM, Bletry O, Dequiedt P, Talasczka A, Rondeau E, Dutel JL, Wechsler B, Piette JC. Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment. Am J Med 103:514-519, 1997 5) Assaly R, Olson D, Hammersley J, Fan PS, Liu J, Shapiro JI, Kahaleh MB. Initial evidence of endothelial cell apoptosis as a mechanism of systemic capillary leak syndrome. Chest 120:1301- 1308, 2001 6) Airaghi L, Montori D, Santambrogio L, Miadonna A, Tedeschi A. Chronic systemic capillary leak syndrome: report of a case and review of the literature. J Intern Med 247:731-735, 2000 7) Fishel RS, Are C, Barbul A. Vessel injury and capillary leak. Crit Care Med 31:S502-S511, 2003 8) Atkinson JP, Waldmann TA, Stein SF, Gelfand JA, Macdonald WJ, Heck LW, Cohen EL, Kaplan AP, Frank MM. Systemic capillary leak syndrome and monoclonal IgG gammopathy: studies in a sixth patient and a review of the literature. Medicine 56:225-239,1977 9) Kim YM, Seok HJ, Kim SH, Kwon SK, Lee JI, Seo JW, Park SK. A case of systemic capillary leak syndrome following upper respiratory tract infection. Korean J Nephrol 22:251-256, 2003.